Publications

Scholarly Journals--Published

  • N.D. Klass, R.P. Baum, M. Schmuecking, N. Presselt, K.M. Mueller, T.G. Wendt, R. Bonnet: Is F-FDG-PET/CT a Valid Non-Invasive Predictor for Regression Grade after Neoadjuvant Treatment in Patients with NSCLC Stage III?. Journal of Cancer 5 (2014), 531-541 (2014)
  • Y. Sayeg, M. Sayeg, R.P. Baum, H.R. Kulkarni, N. Presselt, I. Maeder, A. Kunze, J. Saenger, D. Hoersch, R. Bonnet: Neuroendokrine Neoplasien der Lunge. Pneumologie 68 (2014), 456-477 (2014)
  • D. Schwarzer, I. Maeder, J. Petrovitch, J. Leonhardi, R. Bonnet: Expektoration von Embolisationsspiralen 15 Jahre nach Embolisation pulmonaler arteriovenöserMalformationen bei hereditärer haemorrhagischer Telankiektasie (M. Osler-Weber-Rendu). Pneumologie 68 (2014), 282-285 (2014)
  • H. Wirtz, R. Kropp, J. Behr, u. Costabel, R. Bonnet, N. Schoenfeld, A. Prasse, P. Kardos, V. Seehausen, R. Loddenkemper: 50 Jahre WATL (Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen). Pneumologie 68 (2014), 199-205 (2014)
  • J. Behr, A. Guenther, W. Ammenwerth, I. Bittmann, R. Bonnet, R. Buhl, O.Eickelberg, R. Ewert, S. Glaeser, J. Gottlieb, C, Grohe, M. Kreuter; C. Kroegel, P. Markart, C. Neurohr, M. Pfeifer, A. Prasse, N. Schoenfeld; J. Schreiber, H. Sitter, D. Theegarten, A. Theile, A. Wilke, H. Wirtz, C. Witt, H. Worth, P. Zabel, J. Mueller- Quernheim, U.Costabel: S2- Leitlinie zur Diagnostik und Therapie der idiopatischen Lungenfibrose. Pneumologie 67 (2013), 81-111 (2013)
  • J. Vansteenkiste, M. Zielinski, A. Lindner, J. Dahabrech, E.E. Gonzales, W. Malinowski, M. Lopez_Brea, T. Vanakesa; J.Jassem, H. Kalofonos; J. Perdeus, R. Bonnet, J. Basko, R. Janilionis, B. Passlick, T. Treasure, M.Gillet, F.F. Lehmann, V.G. Brichard: Adjuvant MAGE-3 Immunotherapy in Resected Non-Small-Cell Lung Cancer: Phase II Randomized Study Results. J Clin Oncol 31 (2013), 2396-2403 (2013)
  • D. Hoersch, Y. Sayeg, R. Bonnet, D. Kaemmerer, N. Presselt, R.P. Baum: Expertendialog: Neuroendocrine Tumore der Lunge und des gastroenteropankreatischen Systems: Pneumologie 66 (2012), 44-48 (2012)
  • H. Magnussen, M. Kramer, A. Kirsten, C. Marquette, A. Valipour, F. Stanzel, R. Bonnet, J. Behr, O. Fruchter, Y. Refaely, R. Eberhardt, F. Herth: Effect of Fissure Integrity on Lung Volume Reduction Using a Polymer Sealant in Advanced Emphysema. Thorax 67 (2012), 302-308 (2012)
  • " Treatment of Advanced Emphysema with Emphysematous Lung Sealent (AeriSeal)" Respiration 82 (2011),36 - 45 (2011 - Present)
  • "Polymeric Lung Volume Reduction (AeriSeal) in Patients with advanced heterogen Emphysema"  Pneumologie 65(2011),9 (2011 - Present)
  • " Effect of Polymeric Lung Volume Reduction (PLVR) Therapy on Composite COPD Outcome Measures" (2011 - Present)
  • " CT Assessment of Regional Lung Volume Changes following Endobronchial Volume Reduction Therapy  in Emphysema Patients using a Synthetic Hydrogel Foam" Am j Respir Crit Care Med 181(2010), A5533 (2010 - Present)
  • " Effective Endobronchial Volume Reduction Therapy for Emphysema using Synthetic Adhesive Hydrogel- Foam" Am j Respir Crit Care Med 181 (2010),A5173 (2010 - Present)
  • "Dose- Finding Study of Polymeric Lung- Volume- Reduktion in Patients with advanced Emphysema" Pneumologie 64 (2010),165 (2010 - Present)
  • The Will Rogers Phenomenon" Pneumologie 63 (2009), 36 (2009 - Present)
  • "Repiratoric Insufficiency in Paraplegia" Pneumologie 63 (2009), 7 (2009 - Present)
  • Reck, M., J. von Pawel, H.-N. Macha, E. Kaukel, K.-M. Deppermann, R. Bonnet, K. Ulm, S. Hessler, U. Gatzemeier. "Efficient Palliation in Patients with Small-Cell Lung Cancer by a Combination of Paclitaxel, Etoposide and Carboplatin: Quality of Life and 6-Years-Follow-Up Results from a Randomized Phase III Trial." Lung Cancer 53. (2006): 67-75. Purpose: Based on the promising (01/2006)
  • Schmuecking, M., R. P. Baum, R. Bonnet, K. Junker, K.-M. Müller. "Korrelation histologischer und nuklearmedizinischer Befunde der Tumorregression in behandelten bösartigen Lungentumoren." Pathologe 26. (2005): 178-190. (01/2005)
  • Karg, O., R. Bonnet, H. Magnussen, D. Köhler, J. Geissler, P. Haidl, I. Mäder, B. Schucher. "Atmungstherapeut - Einführung eines neuen Berufsbildes." Pneumologie 58. (2004): 850-853. (12/2004)
  • Maeder, I., ,R. Bonnet. "Dyskenisie der Atemwege." Atemweg.-Lungenkrkh. 30. (2004): 496-498. (12/2004)
  • Gridley, D.S., R. Bonnet, D. A. Bush, C. Franke, G. A. Cheek, J. D. Slater, J. M. Slater. "Time course of Serum Cytokines in Patients Receiving Proton or Combined Photon/Proton Bwam Radiation for Resectable but Medically Inoperable Non-Small-Cell Lung Cancer." Intern. Journal Radiation Oncology Biol. Phys. 60. (2004): 759-766. Purpose: We prospectively measured the levels of basic fibroblast growth factor (bFGF), tumor necrosis factor-Alpha (TNF-alpha), interleukin (IL)-1Beta, IL-6, IL-10, and procollagen III peptide (P III P) in serum from non-small-cell lung cancer patients treated with photons combined with protons or protons alone. These factors were quantified because they may be extremely important in the development of side effects, and the treated volume integral dose may be crucial in inducing them. Methods:Of the 12 participating patients, 6 with squamous cell carcinoma (SCC) and 3 with adenocarcinoma received combined photon/proton beam radiation, whereas 2 with SCC and 1 with large-cell carcinoma (LCC)received only proton radiation. Mean age was 73.6 years. There were 4 male and 8 female patients with a mean smoking history of 87.0 packyears. Nine patients had Stage 1, 2 had II, and 1 had stage IIIa lung cancer. Serum samples were obtained at baseline and on Days 15,30,45,60,90,120,150,180 and 210 after initiation of radiation therapy. Injury scores for pneumonitis and fibrosis based on computed tomography (CT) scans were assigned. Results: The percentage of lung volume irradiated was significantly less for patients treated with protons alone compared with those receiving photon plus proton therapy. Injury scores were also lower for proton only treatment (p = 0,039). When evaluated collectively, bFGF, TNF-Alpha, and IL-6 concentrations were significantly higher in the photon/proton group; radiation regimen, but not time after treatment initiation, was a significant factor in their levels. P III P level was also higher in the photon/proton patients and both radiation regimen and time after treatment had an impact. Conclusions: Although significant changes occurred in some of the measured cytokines and P III P, it was the difference in the volume integral dose that occurred when protons were used alone vs. mixed photon/proton therapy that correlated with the incidence of pneumonitis and/or fibrosis. However, it cannot be ruled out that differences in cytokine levels before radiotherapy initiation may have contributed to the outcome. (12/2004)

Abstract

  • (PEER REVIEWED) Schmuecking M., C.G. Blumstein, J. Leonhardi, R.P. Baum, N. Presselt, C.P. Schneider, T:G: Wendt, R. Bonnet, B. Krause, P. Messer, R. Wurm, K.D. Hamm, E. Roettinger, S.N. Reske, N.M. Blumstein: . "Verändertes Therapiemanagement durch PET ? Prospektive Analysen für verschiedene Tumorentitäten mit unterschiedlichen PET-Tracern. ." Strahlenther Onkol S1 181,S1. (2005): 83-. (01/2005)
  • (PEER REVIEWED) Schmuecking, M., J. Hagg, J. Leonhardi, R.P. Baum, T.G. Wendt, N. Presselt, C.P. Schneider, R. Bonnet, R. Messer, A.K. Buck, R. Wurm, K.D. Hamm, E. Roettinger, S.N. Roeske, N.M. Blumstein: . "Ist eine molekulare Bestrahlungsplanung mittels PET klinisch relevant? Prospektive Analyse für verschiedene Tumorentitäten mit unterschiedlichen PET-Tracern. ." . Strahlenther Onkol 181,S1. (2005): 82-. (01/2005)
  • (PEER REVIEWED) Schmuecking, M., C.P. Schneider, J. Soeldner, J. Leonhardi, N. Presselt, M Scheithauer, R.P. Baum, K.M. Mueller, T.G. Wendt, R. Bonnet: . "What is the role of F-18 FDG PET within randomized multicenter clinical trials for multi-modality treatment of non-small lung cancer stage III?." J Clin Oncol 23,S16. (2005): 665s-. (01/2005)
  • (PEER REVIEWED) Schmuecking, M., A. Niesen, R. B. Bonnet, C. P. Schneider, N. Presselt, T. G. Wendt, R. P. Baum: . "Ist der F-18 FDG Uptake (SUV) wirklich ein unabhängiger Prognoseparameter für nicht-kleinzellige Lungenkarzinome? ." Nuklearmedizin 44. (2005): A 138 -. (01/2005)
  • (PEER REVIEWED) Maeder, I., R. Bonnet:. "Bronchoskopische Fibrinklebung als Mittel der Wahl bei iatrogenen Tracheaverletzungen. ." Pneumologie 59. (2005): S37-. (01/2005)
  • (PEER REVIEWED) Schmuecking, M., R.P.Baum, S,M. Liesenfeld, M. Scheithauer, N. Presselt, C.P. Schneider, A. Niesen, J. Leonhardi, T.G. Wendt, J. Dunst, K.H. Kloetzer, U. Schalldach, J. Scheibe, R. Bonnet: . "Molecular radiation treatment planning with F-18 FDG-PET in non-small cell lung cancer (NSCLC)." Journal of Nuclear Medicine 45 S. (2004): 37P-. (12/2004)
  • (PEER REVIEWED) Maeder, I., R. Bonnet. "Argonplasmakoagulation in der Therapie der schweren Tracheabronchopathia osteochondroplastica. ." Atemw.-Lungenkrkh. 30. (2004): 527-. (12/2004)
  • (PEER REVIEWED) Maeder, I., R. Bonnet: . "Argonplasmacoagulation (APC) is the treatment of choice in the therapy of severe tracheopathia osteochondroplastica (TPO). ." Proceedings XIII th World Congress for Bronchology, Barcelona . (2004): P018-. (12/2004)
  • (PEER REVIEWED) Maeder, I., R. Bonnet: . "Bronchoscopic fibrin sealing is the treatment of choice in iatrogenic tracheal injuries. ." Proceedings XIII th World Congress for Bronchology, Barcelona . (2004): P053-. (12/2004)
  • (PEER REVIEWED) Weber, M., R. Bonnet, A, Schmidt, J. Sänger. "Adjuvante medikamentöse Therapie einer pulmonalen Mycobacterium-abscessus-Infektion mit Interferon-Gamma bei einem immunkompetenten Patienten. ." Atemw.-Lungenkrkh 30 . (2004): 529 -. (12/2004)
  • (PEER REVIEWED) Maeder, I., R. Bonnet. "Bronchoskopische Fibrinklebung als Mittel der Wahl bei iatrogenen Tracheaverletzungen. ." Atemw.-Lungenkrkh. 30. (2004): 528-. (12/2004)
  • (PEER REVIEWED) Schmuecking, M., R.P. Baum, S.M. Liesenfeld, M. Scheithauer, N. Presselt, C.P. Schneider, A. Niesen, J. Leonhardi, A. Proeschild, T.G. Wendt, R. Bonnet. "Is the F-18FDG uptake (SUV) an independent prognostic factor for non-small cell lung cancer (NSCLC)?." Journal of Nuclear Medicine 45, S. (2004): 373P-. (12/2004)
  • (PEER REVIEWED) Bonnet, R., R. Rosell, J. Strausz, E. Sanches, M. Provencio, J.-M. Vernejoux, H. Lena, M. L. Gershanovich, B. Boussard, J. von Pawel. ": Irinitecan (Iri) plus docetaxel (Doc) every 3 weeks in chemotherapy naïve patients (pts) with inoperable non-small cell lung cancer (NSCLC): results of a phase II study. ." Annals of Oncology 15,S3. (2004): iii177 -. (12/2004)
  • (PEER REVIEWED) Schneider, C.-P., R. Bonnet. "First-line treatment with docetaxel and platinum in patients with advanced non-small cell lung cancer (NSCLC): Clinical experience from a single institution. ." Annals of Oncology 15,S3. (2004): iii178-. (12/2004)
  • (PEER REVIEWED) Schmuecking, M., R.P. Baum, S. M. Liesenfeld, N. Presselt, C.P. Schneider, A. Niesen, J. Leonhardi, R. Bonnet. T.G. Wendt, A. Schmidt, K. M. Mueller. "Correlation of metabolic remission and histological regression with survival in locally advanced lung cancer.." Journal of Nuclear Medicine 45, S. (2004): 37P-. (12/2004)